Why Cibus, Inc.’s (CBUS) Stock Is Up 5.29%
As of Monday, July 27, Cibus, Inc.’s CBUS share price has surged by 5.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Commentary & Analysis
Why Cibus, Inc.’s (CBUS) Stock Is Up 6.25%
As of Tuesday, July 21, Cibus, Inc.’s CBUS share price has surged by 6.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cibus, Inc.’s (CBUS) Stock Is Down 6.25%
As of Thursday, July 16, Cibus, Inc.’s CBUS share price has dipped by 6.25%, which has investors questioning if this is right time to buy.Michael Rose
Why Cibus, Inc.’s (CBUS) Stock Is Down 7.11%
As of Wednesday, July 15, Cibus, Inc.’s CBUS share price has dipped by 7.11%, which has investors questioning if this is right time to buy.Michael Rose
Why Cibus, Inc.’s (CBUS) Stock Is Up 7.04%
As of Tuesday, July 14, Cibus, Inc.’s CBUS share price has surged by 7.04%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CBUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $147.3 | $251.9 | 25% |
|
| Shares Out (Mil) | 65.2 | 50.8 | 54% |
|
| Institutional Ownership | 57.2% | 92.0% | 38% |
|
| Float (Mil) | 57.2 | 40.5 | 50% |
|
| Beta | 1.65 | 0.95 | 86% |
|
| Avg Daily Volume (000s) | 155 | 447 | 41% |
|
| Price Change (52-week) |
24.5% | 54.2% | 65% |
|
| Growth | CBUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (31.5%) | 14.0% | 1% |
|
| Net Income (5yr) | (23.2%) | (9.8%) | 17% |
|
| EPS (5yr) | 47.0% | 16.3% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 72.3% | (15.6%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.190) | ($0.725) | ($0.630) | |
| Month Ago EPS | ($0.190) | ($0.725) | ($0.630) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.120) | ($0.450) | ($0.200) | |
| Year/Year Chg | (41.5%) | (73.9%) | (82.4%) | |
| Financials | CBUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $39 | 5% |
|
| Net Income (TTM) (Mil) | ($101) | ($43) | 11% |
|
| EPS (TTM) | ($1.903) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($50) | ($30) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $3 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $273 | $5 | 53% |
|
| Enterprise Value (Q1) (Mil) | $428 | $182 | 33% |
|
| Valuation | CBUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.11 | 2.60 | 74% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CBUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (30.8%) | (49.7%) | 17% |
|
| ROE | (191.8%) | (55.4%) | 5% |
|
| Liabilities to Assets | 89.1% | 30.3% | 84% |
|
| F-Score | 5 | 3 | 51% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Insider Net Purchases Screen
Factors: Other
A stock screen designed to find small-cap companies that have more stock purchased than sold by insiders.
| Performance Since Inception: | -2.2% |
| +/- S&P 500: | -9.7 |
